Abstract
There are some evidences regarding beneficial effects of carnitine in improvement of depression symptoms. Incidence of depression is significantly higher among HIV positive individuals compared to HIV negative populations. Also carnitine deficiency is prevalent in HIV positive individuals.
In a cross-sectional study correlation between serum carnitine level and depression severity based on the Beck Depression Inventory questionnaire was assessed in 100 HIV/AIDS (42 males and 58 females) patients. According to the Beck Depression Inventory definitions, 31%, 16%, and 21% of the patients experienced mild, moderate, and severe depression, respectively.
The mean ± SD serum concentration of total carnitine in the patients was 37.96 ± 26.08 (µmol/L). Fifty-four (54%) patients were categorized as carnitine deficient. A non-statistically significant negative correlation between patients’ depression scores and total levels of serum carnitine was found. Considering the prevalence of depression among HIV/AIDS patients and probable role of carnitine in the pathogenesis of depressive disorders, more studies are needed to reveal correlation between depression and the body storage of carnitine.
Keywords: Depression, carnitine, HIV/AIDS.
Current HIV Research
Title:Frequency of Depression and its Correlation with Serum Carnitine Level in HIV/AIDS Patients
Volume: 11 Issue: 3
Author(s): Haleh Rezaee, Hossein Khalili, Shima Hatamkhani, Simin Dashti-Khavidaki and Zahra Khazaeipour
Affiliation:
Keywords: Depression, carnitine, HIV/AIDS.
Abstract: There are some evidences regarding beneficial effects of carnitine in improvement of depression symptoms. Incidence of depression is significantly higher among HIV positive individuals compared to HIV negative populations. Also carnitine deficiency is prevalent in HIV positive individuals.
In a cross-sectional study correlation between serum carnitine level and depression severity based on the Beck Depression Inventory questionnaire was assessed in 100 HIV/AIDS (42 males and 58 females) patients. According to the Beck Depression Inventory definitions, 31%, 16%, and 21% of the patients experienced mild, moderate, and severe depression, respectively.
The mean ± SD serum concentration of total carnitine in the patients was 37.96 ± 26.08 (µmol/L). Fifty-four (54%) patients were categorized as carnitine deficient. A non-statistically significant negative correlation between patients’ depression scores and total levels of serum carnitine was found. Considering the prevalence of depression among HIV/AIDS patients and probable role of carnitine in the pathogenesis of depressive disorders, more studies are needed to reveal correlation between depression and the body storage of carnitine.
Export Options
About this article
Cite this article as:
Rezaee Haleh, Khalili Hossein, Hatamkhani Shima, Dashti-Khavidaki Simin and Khazaeipour Zahra, Frequency of Depression and its Correlation with Serum Carnitine Level in HIV/AIDS Patients, Current HIV Research 2013; 11 (3) . https://dx.doi.org/10.2174/1570162X11311030007
DOI https://dx.doi.org/10.2174/1570162X11311030007 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Gene Therapy Approaches in an Autoimmune Demyelinating Disease: Multiple Sclerosis
Current Gene Therapy Morphofunctional Aspects of the Blood-Brain Barrier
Current Drug Metabolism Targeting the Prokineticin System to Control Chronic Pain and Inflammation
Current Medicinal Chemistry The Framingham Brain Donation Program: Neuropathology Along the Cognitive Continuum
Current Alzheimer Research Current Updates on Bone Grafting Biomaterials and Recombinant Human Growth Factors Implanted Biotherapy for Spinal Fusion: A Review of Human Clinical Studies
Current Drug Delivery New Challenges in CNS Repair: The Immune and Nervous Connection
Current Immunology Reviews (Discontinued) Brain Hyperthermia During Physiological and Pathological Conditions: Causes, Mechanisms, and Functional Implications
Current Neurovascular Research Magnesium in Pain Research: State of the Art
Current Medicinal Chemistry Perspectives in Engineered Mesenchymal Stem/Stromal Cells Based Anti- Cancer Drug Delivery Systems
Recent Patents on Anti-Cancer Drug Discovery Neurovascular Matrix Metalloproteinases and the Blood-Brain Barrier
Current Pharmaceutical Design Transforming Growth Factor-β Signaling in Motor Neuron Diseases
Current Molecular Medicine Motor Control in the Human Spinal Cord and the Repair of Cord Function
Current Pharmaceutical Design Collective Roles of Molecular Chaperones in Protein Degradation Pathways Associated with Neurodegenerative Diseases
Current Pharmaceutical Biotechnology The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
Current Medicinal Chemistry Pharmacological Intervention of Cyclooxygenase-2 and 5-Lipoxygenase Pathways. Impact on Inflammation and Cancer
Current Pharmaceutical Design Oxidative Stress and Opioids' Toxicity: An Update
Mini-Reviews in Organic Chemistry Directions for Enhancement of the Therapeutic Efficacy of Mesenchymal Stem Cells in Different Neurodegenerative and Cardiovascular Diseases: Current Status and Future Perspectives
Current Stem Cell Research & Therapy Stem Cells in Pharmaceutical Biotechnology
Current Pharmaceutical Biotechnology Neuropeptide Conversion to Bioactive Fragments - An Important Pathway in Neuromodulation
Current Protein & Peptide Science Combining Angiogenesis Inhibitors with Radiation: Advances and Challenges in Cancer Treatment
Current Pharmaceutical Design